InxMed (Hong Kong) Limited serves as a key Hong Kong-registered entity within the InxMed group, a clinical-stage biotechnology company dedicated to developing therapies that overcome tumor resistance in oncology.
Founded in 2017 with headquarters in Nanjing, China, InxMed focuses on targeting critical pathways such as focal adhesion kinase (FAK) and the tumor microenvironment to address drug resistance across multiple cancer types. Its lead product, ifebemtinib (IN10018), is a highly selective oral FAK inhibitor advancing through late-stage clinical trials in China and has garnered Breakthrough Therapy Designations from the National Medical Products Administration (NMPA) for several indications and Fast Track Designation from the U.S. FDA.
The company's pipeline encompasses additional FAK inhibitors, bispecific antibodies, and antibody-drug conjugates (ADCs) designed to enhance efficacy in combination therapies. InxMed operates globally with clinical development in the United States and partnerships with major pharmaceutical firms. In September 2026, InxMed entered into a worldwide license agreement with Chugai Pharmaceutical Co., Ltd. for SPYK04, a novel RAF-MEK molecular glue, granting exclusive rights to develop, manufacture, and commercialize the asset worldwide in exchange for upfront payments and royalties.
As part of its growth strategy, the InxMed group has filed for listing on the Hong Kong Stock Exchange and raised significant funding from investors including SDIC Capital and Fosun. The company positions itself as an innovator in post-resistance cancer treatments with a strong emphasis on translational research and combination strategies.
Also known as 應世生物（香港）有限公司, iPharma (H.K.) Limited, InxMed Limited, and 應世生物.
Exclusive deal grants development, manufacturing and commercialisation rights for a RAF‑MEK molecular glue; Chugai to receive upfront, royalties and a share of sublicense income.
